Phase I metabolism of ganstigmine. Rat, dog, monkey and human liver microsomal extracts investigated by liquid chromatography electrospray tandem mass spectrometry.

J Mass Spectrom

Chiesi Farmaceutici SpA, R&D, Analytical Chemistry and Pharmacokinetics Departments, Via Palermo 26/A, I-43100 Parma, Italy.

Published: December 2001

AI Article Synopsis

Article Abstract

Ganstigmine, a new acetylcholinesterase inhibitor, was incubated with rat liver microsomes and the resulting metabolites were identified by high-performance liquid chromatographic/mass spectrometric (HPLC/MS) and HPLC/MS/MS analyses. The results showed the formation of eight main metabolites, among which geneseroline and molecules corresponding to mono-hydroxylated, demethylated and reduced ganstigmine. The metabolic profile drawn for humans, dog and monkey showed a pattern very similar to that of rat: only in the case of liver dog microsomes higher amounts of geneseroline and of a metabolite identified as demethylated and reduced drug were detected.

Download full-text PDF

Source
http://dx.doi.org/10.1002/jms.228DOI Listing

Publication Analysis

Top Keywords

dog monkey
8
demethylated reduced
8
phase metabolism
4
metabolism ganstigmine
4
ganstigmine rat
4
rat dog
4
monkey human
4
human liver
4
liver microsomal
4
microsomal extracts
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!